PureHealth’s Dh600m Payout Boost Delivers 3.5% Yield for UAE Investors
The Abu Dhabi–listed healthcare giant PureHealth has proposed a Dh600 million cash dividend for FY 2025, a step that immediately raises the bar on shareholder payouts across the local bourse.
Why This Matters
• Bigger cheques – The Dh600 million plan is 75% larger than last year’s maiden payout, signalling PureHealth’s confidence in recurring cash generation.
• Semi-annual instalments – Shareholders would receive two equal payments, improving liquidity planning for retail investors and pension funds alike.
• 30% payout ratio – The proposal still leaves substantial headroom for reinvestment, hinting at further overseas acquisitions.
• ADX benchmark effect – A richer dividend from a heavyweight could pressure other Abu Dhabi Securities Exchange constituents to review their own payout policies.
Inside the Numbers
PureHealth closed 2025 with Dh2 billion in net profit, up 17.7% year-on-year, on revenue of Dh27.3 billion. Operating leverage was evident: EBITDA advanced 16.1% to Dh4.8 billion, while pre-tax earnings climbed 26.1%. Roughly 72% of revenue flowed from the Care vertical – hospitals, diagnostics and tech – and the remaining 28% came from Cover, the insurance arm led by Daman.
Two operational highlights dominated analyst calls:
Insurance underwriting discipline that lifted Cover’s first-half profit by 56%.
A late-year completion of the 60% stake in Hellenic Healthcare Group, adding 11 hospitals in Greece and Cyprus.
Strategy Behind the Cheque
Management framed the payout as a “confidence signal” rather than a cash-offload. Chairman H.E. Kamal Al Maazmi said the group is “only dipping a toe” into its distributable reserves; 70% of 2025 earnings will still fund expansion, digital platforms and bolt-on deals.
Key motives:
• Post-listing credibility – Listed in December 2023, PureHealth wants to establish a predictable dividend rhythm similar to mature global peers.
• Cost of capital advantage – A growing dividend yield can tighten the spread on future bond issues, useful if interest rates remain sticky.
• Peer pressure – Other ADX newcomers such as ADNOC Gas and Lulu are pursuing payout sweeteners; PureHealth’s move intensifies that race.
Market Watch
The announcement landed after market close on 9 February 2026. PureHealth shares opened flat the next morning at Dh4.83, though brokers noted an immediate 20% spike in bid depth, suggesting yield-hunters are accumulating. Sell-side consensus currently pins a 12-month target at Dh5.60, implying 16% upside before factoring in the cash dividend.
Fund managers told The National they expect index-tracking funds to rebalance once regulatory approval is secured, potentially boosting daily turnover. Meanwhile, regional rivals such as Saudi-listed healthcare provider Mouwasat dropped 1.4% intraday, underscoring competitive sentiment.
What This Means for Residents
• Retail investors – With most UAE savings accounts paying sub-1% interest, a dividend yield approaching 3.5% makes PureHealth a serious contender for everyday portfolios on ADX’s e-platforms.
• Policyholders – The stronger balance sheet underpins the group’s insurance arm, suggesting stable premium pricing for Daman customers even as medical inflation runs around 4%.
• Healthcare professionals – Expansion capital will funnel into new outpatient facilities and AI-assisted labs, translating into fresh hiring rounds across nursing, tech and administration.
• Small suppliers – A heftier cash buffer reduces payment-cycle risk for local pharmaceutical and logistics SMEs that service PureHealth hospitals.
Regulatory & Timing Checklist
Board approval – Already secured on 9 February 2026.
Securities and Commodities Authority (SCA) review – Standard clearance expected within a month.
Shareholder vote at the AGM – Tentatively slated for late April.
Record dates – If approved, first tranche likely hits investor accounts by early-June; the second in December.
Looking Ahead
PureHealth’s stated ambition is to allocate up to Dh15 billion for cross-border deals through 2028. Executives hinted at “active dialogues” in Southeast Asia and Central Europe, where fragmented private-hospital markets offer synergy upside.
Given the group’s 50% asset exposure outside the UAE, analysts caution that currency swings and overseas regulatory risks could temper profit growth. Still, the discipline of a recurring dividend may force tighter capital allocation and, by extension, support share-price stability.
For UAE residents watching the intersection of healthcare quality and investment opportunity, PureHealth’s larger-than-expected dividend signals both financial muscle and a maturing local capital market where dividends—not just capital gains—are becoming part of the conversation.